Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Notice of Annual General Meeting

Tuesday, October 15, 2024 1 min read
Key Takeaway: Radiopharm Theranostics has announced the initiation of a Phase 1/2a clinical study for BetaBart (RV-01) and received IND approval from the US FDA. The company is making significant progress in its clinical programs, showcasing positive updates across four different initiatives. This marks a promising step in their therapeutic development efforts.

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics is advancing its clinical programs.
  • The company received IND approval from the FDA for a new study.
  • Positive updates were shared across multiple programs.

Full Press Release Details

• Announcements
• October 15, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• September 1, 2022
• Announcements
• February 28, 2022
• Announcements
• July 23, 2024
• Announcements
• October 25, 2022

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the latest update from Radiopharm Theranostics?

Radiopharm Theranostics has initiated a Phase 1/2a clinical study for BetaBart (RV-01).

What approval did Radiopharm receive from the FDA?

The company received IND approval from the US FDA to start its therapeutic clinical study.

How many clinical programs are being updated?

Radiopharm shared positive updates across four different clinical programs.

Tags: RADX Viatris Investor Conferences Healthcare BetaBart Phase 1/2a FDA IND approval clinical programs
Last updated: Oct 15, 2024